DNA X is no longer a rugged-handset company. In January the former Sonim Technologies sold that business and kept a Nasdaq listing around an unfinished crypto-trading site bought from a related party. The mid-year print is not an operating quarter. It is a recapitalization story. Continuing operations produced no revenue against a mid-year cash balance of $0.9 million. The trading website stayed closed to the public while the company tested new services. A related-party sponsor later swapped a convertible note for preferred stock after Nasdaq staff issued a delisting determination on the stockholders-equity rule.
The phone and hotspot sale produced a pretax gain of $15.3 million. First-half net income of $5.1 million exists only because of that discontinued gain. Cash used in operations totaled $5.5 million in the first half. After quarter-end the related-party buyer funded $5.0 million of preferred stock and cancelled the remaining note. Nasdaq later told the company it had regained the equity minimum, but the listing stays under a panel monitor. The common equity is therefore a residual claim on a still-dark platform, a sponsor-controlled recap, and a listing that can be pulled again if equity slips.
Second-quarter general and administrative expense was $1.3 million. That run-rate still consumes cash faster than any trading commission can appear. Management has scheduled a public relaunch for late in the third quarter or early in the fourth. Whether those first commissions arrive before the Nasdaq monitor period and the related-party preferred conversion define the residual common is the entire case.